Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

NCT02689284 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT02689284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Lead sponsor
MacroGenics
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2016
Completion date
January 31, 2021
Enrollment
95 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer, stomach cancer